Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
-
J Korean Soc Biol Psychiatry. 2003 Jun;10(1):3-19. Korean. Original Article.
Lee JN , Yang BH .
Seoul National Hospital, Seoul, Korea.
Department of Neuropsychiatry, College of Medicine & the Mental, Health Research Institute, Hanyang University, Seoul, Korea.
Abstract

The use of atypical antipsychotics is limited by occurrence of adverse reactions such as weight gain, despite of their benefits. This article provides a comprehensive review and discussion of the most significant findings regarding obesity-related pathways and integrates these with the known mechanism of atypical antipsychotic action. The focus of this article is primarily on the genetics of obesity related pathways that may be disrupted by atypical antipsychotics. This review also discussed weight gain, hyperglycemia or occurrence of diabetes while being treated with atypical antipsychotics from the point of view of pharmacogenetics. Pharmacogenetic research seeks to uncover genetic factors that will help clinicians identify the best treatment strategies for their patients. It will aid clinically in the prediction of response and side effects, such as antipsychotic-induced weight gain, and minimize the current "trial and error" approach to prescribing in the near future. This article also presents the genetics of both central and peripheral pathways putatively involved in antipsychotic-induced weight gain while providing a comprehensive review of the obesity literature. This article also review obesity related candidate molecules which may be disrupted during atypical antipsychotic drug treatment.

Copyright © 2019. Korean Association of Medical Journal Editors.